Document:

exhibit10_2.htm

EXHIBIT 10.2

 

**-CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION.  CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

 

2012 PFIZER PREMIER EQUINE PRODUCTS DISTRIBUTION AGREEMENT

 

 

This Agreement dated and effective as of January 1, 2012 is made by and between Pfizer Inc, 5 Giralda Farms Madison, New Jersey 07940-1027 (hereinafter, "PFIZER") and MWI VETERINARY SUPPLY COMPANY, 3041 W. Pasadena Drive, Boise, ID 83705 (hereinafter, "MWI").

 

1. PFIZER hereby appoints MWI, and MWI hereby accepts appointment, as a contract distributor for PFIZER Products set forth on Exhibit A (the "Products"), to purchase from PFIZER and to resell for MWI's own account as a distributor, subject to the following terms and conditions.

 

2. MWI recognizes and agrees to the following:

(a) PFIZER has elected to work with a select group of distributors that are committed to maximizing the sale of the Products and to working closely with PFIZER to identify market opportunities for both companies. The intent of this Agreement is to attain that goal;

(b) PFIZER intends to utilize this group of distributors to sell the Products to customers below them in the distribution chain and that PFIZER has, and may in the future, run promotions and other activities that would be seriously prejudiced if MWI resells the Products to other PFIZER contract distributors, non-employee agents or through brokers.

 

3. Accordingly, MWI shall:

(a) use its reasonable best efforts to sell the Products by focusing its primary effort at reselling to veterinarians, OTC retailers, and horse owners;

(b) maintain a full-time outside and inside sales force that will personally and actively solicit sales of the Products and pay such sales representatives reasonable commission as MWI deems appropriate, but no less than the minimum commission schedule in Exhibit A;

(c) MWI will be eligible for an additional /**/ Premier RSA if at least the amount equivalent to commissions designated in Exhibit A is paid to its sales representatives.

(d) store and handle its inventory of Products under conditions that will ensure that such Products retain their potency, purity, quality, and identity;

(e) MWI will provide PDA/EDI with sales out data on each PFIZER sku MWI sells. MWI will provide to Covansys its Health Industry Number, Customer Health Industry Number, PFIZER product number, transaction date, ship to zip code, number of units and price with respect to each sale of product, and unit inventories on each PFIZER sku that MWI sells. This information should be sent to Covansys. Sales out data shall be provided to Covansys within ten (10) working days of the date of each invoice. MWI will use its best efforts to insure sales out data integrity and timeliness;

(f) set its resale prices for the Products independently and at its sole discretion;

(g) cooperate fully with PFIZER by actively participating in such strategy sessions as PFIZER reasonably may require, for the purpose of developing programs to increase use of the Products; and to cooperate fully with PFIZER in implementing all promotions and sales campaigns for the Products;

(h) allow PFIZER's representatives to attend and actively participate in meetings of MWI's sales representatives;

(i) distribute the Products only under the labeling provided by PFIZER; prescribe, recommend, suggest, and advertise each Product for use only under the conditions stated in the labeling provided by PFIZER; and observe all federal, state, and local laws governing the distribution of animal drugs. In the case of Products bearing the legend, "CAUTION: FEDERAL LAW RESTRICTS THIS DRUG TO USE BY OR ON THE ORDER OF A LICENSED VETERINARIAN," or any similar legend, sell such Products only to or on the order of a licensed veterinarian for use in the course of his or her professional practice or to another person or entity regularly and lawfully engaged in the use, distribution or dispensing of such legend drugs;

(j) MWI agrees that credit limits established by PFIZER shall be subject to change by PFIZER in its sole discretion and that no shipments will be made to MWI in excess of the established credit limits;

(k) take no action, whether or not identified above, that would harm the goodwill or name of PFIZER, or damage the interests of PFIZER or the Products, other than where supported by sound factual evidence. For purposes of this Agreement "Goodwill" shall mean the marketplace advantage of customer patronage and loyalty developed with continuous business under the same name over a period of time.

(l) MWI shall immediately notify PFIZER in the event MWI obtains information indicating that any of the Products may have to be recalled either by virtue of applicable law or regulation or good business judgment. PFIZER shall control all efforts necessary to conduct any such recall. MWI shall cooperate with PFIZER and MWI agrees to maintain adequate records to conduct such recall, including the name, address and Product purchases of all purchasers of PFIZER Products.

(m) MWI may make use of the Product Focus Funds provided for in Exhibit D hereto.

(n) Make payment to PFIZER /**/; and

(o) Provide to PFIZER by the close of business on each day an EDI report 852 report covering all Product inventory purchased from Pfizer and setting forth in dollars at MWI's acquisition cost from Pfizer the amount of inventory by species. MWI agrees that Pfizer shall have the right, upon reasonable advance notice and during business hours to audit inventory in the possession of MWI to confirm compliance with this paragraph 3(n) and to confirm the accuracy of the data contained in the report;

(p) MWI shall be prepared to receive EDI 845 contract notification transactions no later than 6/30/2012.

(q) Each distributor, veterinarian, dealer or producer must make its own independent decision as to whether and how to sell and/or purchase Pfizer Animal Health's Equine products, including at what price to advertise, sell or value Pfizer Animal Health's Equine products. Notwithstanding the above, Pfizer may exclude from rebate calculations any Pfizer Products sold by distributors, veterinarians, dealers or producers below the recommended selling price.

 

4. PFIZER shall:

(a) sell the Products to MWI at the prices in effect in the then current published PFIZER Animal Health Products Distributor Price List (hereinafter, "Price List"). PFIZER also shall permit MWI to participate in the distributor incentive programs offered by PFIZER, in accordance with the terms of such programs. PFIZER shall have the unrestricted right to revise the prices, terms and conditions of the Price List, and to add or delete Products or package sizes, without advance notice to MWI and the revisions shall be effective on all orders submitted after the effective date of the price revisions. In all cases of orders received for other than immediate shipment, the price for the Products shall be that in effect at the time of shipment. PFIZER agrees to give MWI /**/ advance notice of price increases;

(b) compensate MWI in accordance with Exhibits B, C and D hereto. In the event that one Agreement holder acquires or combines with another Agreement holder, the purchase objectives will be adjusted accordingly for the purpose of determining incentives earned; and

(c) allow MWI credit on prepaid returns in accordance with PFIZER's Outdated Products Policy which is in effect at the time.

(d) Agreement holders with more than one location must combine purchases of all locations to determine attainment level for incentives. In the event that one Agreement holder acquires or combines with another Agreement holder, the purchase objectives will be adjusted accordingly for the purpose of determining incentives earned.

(e) Only product purchased directly from Pfizer by MWI and then sold under the terms of this Agreement will be eligible for any rebate, discount, or any other compensation. Any discrepancies must be documented by the Distribution Agreement holder using copies of PFIZER invoices.

(f) Only sales out to customers in the continental United States will be eligible for any rebate, discount, or any other compensation described in this Agreement.

 

5. Nothing in this Agreement shall be deemed to limit PFIZER's ability to sell Products to any other party.

 

6. All purchases by MWI pursuant to this Agreement shall be in accordance with the terms of PFIZER's Pricing and Shipping Policies, as may be amended by PFIZER from time to time. Unless the parties agree otherwise, shipments shall be made to either MWI's central warehouse point or to branch offices at MWI's direction.

 

7. Pfizer reserves the right to allocate purchases such that MWI may not purchase more than two (2) months of MWI's average purchases of the most current Moving Annual Total sales purchases. Exceptions must be approved by Pfizer.

 

8. MWI shall not be provided with any rebate, discount or other compensation for Products handled under this Agreement unless specifically set forth herein. MWI will NOT be eligible to collect an RSA or Performance Payment on any lateral sales to other PFIZER contract distributors or to an unauthorized Pfizer distributor. (It is MWI's obligation to confirm with Pfizer, prior to making a sale, as to whether a distributor is a PFIZER contract distributor or an unauthorized distributor.) Nor shall MWI be eligible to collect an RSA or Performance Payment on sales made through brokers or non-employee agents.

 

9. The following standard conditions shall apply to all sales under this Agreement:

(a) MWI shall cooperate fully with PFIZER in participating fully in the Animal Health Institute Electronic Data Interchange ("AHI EDI") for the reporting of sales and inventory data on a daily basis. The data to be reported shall be as described in the AHI EDI Transaction sets.

(b) all orders are subject to acceptance by PFIZER's Animal Health Headquarters. Title to the goods shall pass to MWI once they have been properly delivered to the address designated by MWI. Products requiring temperature control will be shipped F.O.B. destination;

(c) any tax or other charge upon the sale and/or shipment of the goods now or hereafter imposed by federal, state or municipal authorities shall be paid by MWI. In the event that the price of any article includes transportation charges, any increase or decrease in transportation charges shall be for "MWI's account;

(d) EXCEPT AS SET FORTH IN THIS AGREEMENT, OR IN THE LABELING OF THE PRODUCTS SOLD HEREUNDER, PFIZER MAKES NO EXPRESS OR IMPLIED WARRANTIES WITH RESPECT TO THE PRODUCTS;

(e) PFIZER shall defend and indemnify MWI from all claims resulting from any breach by PFIZER of the warranties set forth in this paragraph 9, and specifically any claim that the Products, as sold by PFIZER, were defective. In the event PFIZER is found by any court of competent jurisdiction to be liable for any claim based in products liability, then PFIZER shall reimburse MWI's reasonable legal fees incurred in the course of cooperating with PFIZER's defense. To be covered by this defense and indemnity, MWI must: promptly notify PFIZER of any such claim; allow PFIZER to fully control the defense and/or resolution of the claim; and cooperate fully with PFIZER in the matter. This defense, indemnity and payment for legal fees shall not apply to claims alleging: MWI alteration, negligent handling or improper storage of the Products; sale of outdated Products; sale or recommendation of the Products for uses or in a manner not set forth in the labeling supplied by PFIZER; or sale of the Products after receipt of notice from PFIZER that such sales should be halted;

(f) in no event shall PFIZER be liable to MWI for special, collateral, incidental, or consequential damages in connection with or arising out of the purchase, resale, or use of the Products. Except as provided under subparagraph 9(e), above, total damages recoverable against PFIZER by MWI shall be exclusively limited to the purchase price of the Products with respect to which damages are claimed;

(g) failure of PFIZER to make or of MWI to take, when due, any delivery (or portion thereof) pursuant to an order hereunder, if occasioned by any circumstance or condition beyond the control of the party so failing, shall not subject the failing party to any liability to the other and, at the option of either party, that order or portion thereof not delivered may be canceled;

(h) acceptance of MWI's order by PFIZER is expressly made conditional upon MWI's acceptance of the conditions of sale as set forth herein, and the prices, terms and conditions of the Price List then in effect, notwithstanding acknowledgment or receipt of MWI's purchase order containing additional or different provisions, or conflicting oral representations by any agent of PFIZER.

 

10. MWI shall not delegate its duty of performance or assign its obligations under this Agreement without the prior written consent of PFIZER.

 

11. MWI and PFIZER agree that, under the specific circumstances delineated herein, PFIZER, at PFIZER's sole discretion may recoup the sums outstanding to it from MWI against those sums which may become due from PFIZER to MWI, in that the obligations arise from mutual transactions. The specific circumstances which will enable PFIZER to initiate recoupment are:

(a) MWI becomes insolvent which shall be defined as:

	
(i)  

	
the sum of MWI's debts is greater than all of MWI property ("Balance Sheet Test"); or

	
(ii)  

	
MWI is generally not paying its debts as they come due; or

	
(iii)  

	
MWI has failed to act in good faith for a period in excess of six months to resolve any outstanding invoice or purchase order issues or reconciliations.

(b) MWI commences a liquidation of its operations by means of a sale of its assets in their entirety or piecemeal; or

(c) MWI ceases its business operations whether or not such cessation is voluntary or involuntary; or

(d) MWI files a proceeding pursuant to the U.S. Bankruptcy Code or any state court proceeding, including an Assignment for the Benefit of Creditors.

 

12. This Agreement shall be effective as of the date first written above and shall continue in force until December 31, 2012. Either party may terminate this Agreement prior to the expiration date (i) with or without cause, upon thirty (30) days written notice to the other party, or (ii) immediately upon written notice, in the event of a material breach by the other party.

 

13. MWI and PFIZER acknowledge that in the performance of their duties hereunder MWI and PFIZER may obtain access to "Confidential Information" (as defined below) of each other. MWI and PFIZER agree that during the term of this Agreement and for a period of five (5) years after the termination of this Agreement, unless specifically permitted in writing by the other party, which permission shall not be unreasonably withheld, especially in connection with the sale of all or a substantial portion of MWI's business, to (a) retain in confidence and not disclose to any third party and (b) use only for the purpose of carrying out their duties hereunder, any such Confidential Information. As used herein the term "Confidential Information" means any information, or data, whether of a business or scientific nature and whether in written, oral or tangible form, relating to PFIZER's and MWI's business or potential business or its research and development activities, not generally available to or known to the public, and not otherwise known to the receiving party, that is disclosed to or learned by the other party pursuant hereto. "Confidential Information" does not mean or include any information: (a) which is, at the time of disclosure, available to the general public; or (b) which following disclosure becomes available to the general public through no fault of the recipient; or (c) which recipient can demonstrate was in its possession before receipt; or (d) which is disclosed to recipient without restriction on disclosure. Upon completion of the work provided for hereunder or other termination of this Agreement each party will return to the other party any documents, or copies thereof, or any product samples, containing or constituting Confidential Information disclosed to or generated by either party in connection with this Agreement. Neither MWI nor PFIZER shall disclose the existence of this Agreement without the consent of the other party hereto.

 

14. This Agreement shall be governed by the laws of the State of New York applicable to contracts to be fully performed therein.

 

15. This Agreement and documents referred to herein embody the entire understanding between the parties hereto, will supersede prior agreements relating to the Products, and may be modified only in writing and signed by the parties to be bound. No activities conducted pursuant to this Agreement or related thereto, including but not limited to the future planning activities of the parties, shall be deemed to give rise to any obligations on the part of either party other than as expressly provided for herein.

 

IN WITNESS WHEREOF, intending to be legally bound, the parties have executed this Agreement.

	
MWI VETERINARY SUPPLY COMPANY

 

 

 

BY:           /s/ James F. Cleary, Jr.                                                      

 

Print Name:  James F. Cleary, Jr.

 

Title:           President and CEO                                                      

 

Date:                February 24, 2012                                                 

 

	
Pfizer Inc.

 

 

 

BY:            /s/ Clinton A. Lewis, Jr.

Clinton A. Lewis, Jr.

President, U.S. Operations

Pfizer Animal Health

 

 

Date:                February 29, 2012

 

Exhibit A

Ethical Equine Distributor Product & RSA List

Pricing will be forthcoming

(Equine - LVSTK Distributor)

EFFECTIVE: January 1, 2012 - December 31, 2012

	
SKU#

	
DESCRIPTION

	
Rx

	
UNIT

	
Units/

Shipper

Min.

Quantity

	
RSA

Eligible

	
RSA

%

	
Premier

RSA**

	
Rep

Commission*

	
Performance

Eligible

	  
	
ANTI-INFLAMMATORIES

	  
	
1424

	
Depo-Medrol, 40 mg/ml

	
Rx

	
5ml

	
24

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
1426

	
Depo-Medrol, 20 mg/20 ml

	
Rx

	
20ml

	
25

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2187

	
Domoso Gel

	
Rx

	
60 gm

	
1

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2188

	
Domoso Gel

	
Rx

	
120 gm

	
1

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2189

	
Domoso Solution

	
Rx

	
16 oz

	
1

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2190

	
Domoso Solution

	
Rx

	
Gallon

	
1

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
1432

	
Hylartin V

	
Rx

	
2 ml

	
48

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2193

	
Ketofen

	
Rx

	
50 ml

	
1

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2194

	
Ketofen

	
Rx

	
100 ml

	
1

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
1478

	
Predef 2X

	
Rx

	
100 ml

	
6

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
1489

	
Solu-Delta Cortef, 100 mg

	
Rx

	
10 ml

	
24

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
1490

	
Solu-Delta Cortef, 500 mg

	
Rx

	
10 ml

	
24

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2209

	
Torbugesic, 10 mg

	
CIV

	
10 ml

	
1

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2210

	
Torbugesic. 10 mg

	
CIV

	
50 ml

	
1

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
ANTI-INFECTIVES

	  
	  	  	  	  	  	  	
/**/

	
/**/

	  
	
Excede

	
Rx

	
200mg

	
10

	
/**/

	
/**/

	
/**/

	  
	
1506

	  
	
1465

	
Naxcel

	
Rx

	
1 gm

	
12

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
1466

	
Naxcel

	
Rx

	
4 gm

	
6

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
1463

	
Sterile Water

	  	
80 ml

	
6

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
1464

	
Sterile Water

	  	
20ml

	
12

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
1519

	
Tucoprim Powder

	
Rx

	
400 gm

	
20

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
1494

	
Tucoprim Powder

	
Rx

	
2000 gm

	
1

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
ANTISEPTICS

	  
	
2198

	
Nolvasan Suspension

	  	
28 ml

	
1

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2055

	
Nolvasan Solution

	  	
Gallon

	
1

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2049

	
Nolvasan S

	  	
16 oz

	
1

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2050

	
Nolvasan S

	  	
Gallon

	
1

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2053

	
Nolvasan Skin and Wound Cleanser

	  	
4 oz

	
1

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2054

	
Nolvasan Skin and Wound Cleanser

	  	
8 oz

	
1

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2056

	
Nolvasan Surgical Scrub

	  	
16 oz

	
1

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2057

	
Nolvasan Surgical Scrub

	  	
Gallon

	
1

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
BIOLOGICALS

	  
	
2114

	
Arvac Arteritis Vaccine

	  	
10 x 1ds

	
10

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2116

	
Equiloid Innovator

	  	
12 x 1ds

	
12

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2117

	
Equiloid Innovator

	  	
10ds

	
1

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2119

	
Equivac Innovator EHV 1/4

	  	
10ds

	
1

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2120

	
Fluvac Innovator

	  	
12 x 1ds

	
12

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2122

	
Fluvac Innovator

	  	
10ds

	
1

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2139

	
Fluvac Innovator ENV-4/1

	  	
12 x 1ds

	
12

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2141

	
Fluvac Innovator EHV-4/1

	  	
10ds

	
1

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2123

	
Fluvac Innovator 4

	  	
12 x 1ds

	
12

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2125

	
Fluvac Innovator 4

	  	
10ds

	
1

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2128

	
Fluvac Innovator 5

	  	
12 x 1ds

	
12

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2130

	
Fluvac Innovator 5

	  	
10ds

	
1

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2134

	
Fluvac Innovator 6

	  	
12 x 1ds

	
12

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2136

	
Fluvac Innovator 6

	  	
10ds

	
1

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2146

	
Fluvac Innovator Triple-E FT

	  	
12 x 1ds

	
12

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2147

	
Fluvac Innovator Triple-E FT

	  	
10ds

	
1

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2151

	
Pinnacle I.N.

	  	
10 x 1ds

	
10

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2153

	
Pneumabort-K + 1 b

	  	
12 x 1ds

	
12

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2155

	
Pneumabort-K + 1b

	  	
10ds

	
1

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2159

	
Rotovirus

	  	
10ds

	
1

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2160

	
Tetanus Antitoxin

	  	  	  	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2162

	
Tetanus Antitoxin

	  	  	  	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2164

	
Tetanus Toxoid

	  	
12 x 1ds

	
12

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2166

	
Tetanus Toxoid

	  	
10ds

	
1

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2167

	
Triple-E T Innovator

	  	
12 x 1ds

	
12

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2169

	
Triple-E T Innovator

	  	
10ds

	
1

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2181

	
West Nile-Innovator

	  	
12 x 1ds

	
1

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2183

	
West Nile-Innovator

	  	
10ds

	
1

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2172

	
West Nile-Innovator + EW

	  	
10ds

	
1

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2173

	
West Nile-Innovator + EWT

	  	
12 x 1ds

	
12

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2175

	
West Nile-Innovator + EWT

	  	
10ds

	
1

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2177

	
West Nile-Innovator + VEWT

	  	
12 x 1ds

	
12

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2180

	
West Nile-Innovator + VEWT

	  	
10ds

	
1

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
5237

	
Zylexis

	
Rx

	
5 x Ids

	
150

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
PARASITES & INSECTICIDES

	  
	
6045

	
Anthelcide EQ Paste

	  	
Tube

	
72

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2200

	
Quest Sure Dial, 11.6 gm

	  	
Tube

	
40

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2203

	
Quest Plus Equine Oral Gel, 11.6 gm

	  	
Tube

	
40

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2204

	
Quest Plus Equine Oral Gel, 11.6 gm

	  	
Tube

	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
2207

	
Quest Bulk, 11.6 gm

	  	
Tube

	
50

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
8807

	
Solitude IGR

	  	
6 lb pail

	
6

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
8808

	
Solitude IGR

	  	
20 lb Pail

	
2

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
7973

	
Strongid Paste

	  	
Tube

	
72

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
7974

	
Strongid Paste Bulk

	  	
Tube

	
96

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
7969

	
Strongid C

	  	
25 lb Pail

	
36

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
7900

	
Strongid C 2X

	  	
10 lb Pail

	
100

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
7866

	
Strongid C 2X

	  	
50 lb Bag

	
10

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
7972

	
Strongid T

	
Rx

	
Quart

	
6

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	  
	
SEDATIVES & ANESTHESIA

	
1419

	
Carbocaine-V

	
Rx

	
50 ml

	
100I

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
5 ml

	
10

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
6290

	
Dormosedan

	
Rx

	
6291

	
Dormosedan Gel

	
Rx

	
3 ml

	
10

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
6292

	
Dormosedan

	
Rx

	
20 ml

	
10

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
SUPPLEMENTS

	
2185

	
Clovite V

	  	
5 lb

	
1

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
2186

	
Clovite Conditioner

	  	
25 lb

	
1

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
8047

	
Lixotinic

	  	
Gallon

	
4

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
REPRODUCTIVE PRODUCTS

	
1455

	
Lutalyse

	
Rx

	
30 ml

	
96

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
1504

	
Lutalyse

	
Rx

	
100 ml

	
1

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
OTHER PRODUCTS

	
2033

	
Amiglyde V

	
RX

	
48m1

	
1

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
2191

	
Equipoise

	
CIII

	
50 ml

	
1

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
2195

	
Kopertox

	  	
8 oz

	
1

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
2196

	
Kopertox

	  	
16 oz

	
1

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

	
1487

	
Roccal-D Plus

	  	
Gallon

	
4

	
/**/

	
/**/

	
/**/

	
/**/

	
/**/

 * Pfizer reserves the right to audit rep commission payments

** Rep commission must be paid at /**/ as designated in Exhibit A or distributor will be ineligible for Premier RSA

 

Terms of All Equine Produce Shipments:

 

1. All orders must exceed $250 for freight pre-paid.

 

2. All orders will be shipped in specified “Units/Shipper” quantities only.

 

3. All order will receive standard terms.

 

4. Prices are subject to change without notice.

Exhibit B

PFIZER shall compensate MWI in the following ways:

(a)           Reimburse MWI on a /**/ contained in Exhibit A, per the EDI sales out data calculated /**/ contained in the Price List.

Exhibit C

Performance Payment

MWI will be eligible to receive the performance payments set forth in this clause 1 below subject to the eligibility and performance criteria set forth below and MWI's fulfillment of all of the other obligations contained in this Agreement.

To be eligible for the performance payments set forth below, MWI must do each of the following:

	
  

	
1.

	
MWI achieves sales out during the period of January 1, 2012 through December 31, 2012 of at least /**/ in all performance eligible Pfizer Equine Products, which are designated in the Ethical Equine Distributor Product & RSA List found in Exhibit A of this Agreement.

	
  

	
2.

	
MWI is compliant with all points within the Premier Equine Agreement.

The performance payment will be equal to /**/ on sales out:

/**/ to a maximum of /**/

Only EDI data for invoices dated January 1, 2012 through December 31, 2012 and submitted to Covansys by December 31, 2012 and accepted by PFIZER from Covansys by January 5, 2013 will count towards the calculation of sales out for the period.

Only sales by MWI of the products listed in Exhibit A count towards the performance payments under this Exhibit C.

Exhibit D

Product Focus Funds

If MWI fulfills all of the obligations set forth in this Exhibit D, PFIZER will make available up to a maximum of /**/ in Product Focus funds ("PFF") based on MWI executing PFF's which are agreed with PFIZER. Programs that use these funds must be discussed in advance with MWI's PFIZER Strategic Account Manager, submitted in writing to PFIZER's Senior Director of Channel Management and approved in writing by PFIZER's Senior Director of Channel Management prior to the start of the program. PFIZER shall have no obligation to pay MWI PFF's if the parties are unable to agree on the programs to be funded. In addition;

	
1.

	
To be eligible for PFF's, programs must include specific performance metrics and specifics on total PFF's to be spent in the program and how all PFF's would be spent. In no event will MWI be eligible to receive PFF's in excess of /**/

2.           Programs that result in a direct price decrease to the Purchaser will not be supported.

	
3.

	
ALL PFF'S REQUIRE PROOF OF PERFORMANCE AT PROGRAM CONCLUSION. No payment of PFF's will be made by PFIZER to MWI until all proof or performance wrap-ups are submitted.

	
4.

	
All program wrap-ups are to be submitted within forty-five (45) days of completion of the program. Wrap ups for programs that run to year end 2012 should be submitted no later than February 15, 2013 for payment. Any program wrap-ups submitted to PFIZER after February 15, 2013 for 2012 programs will be paid of out 2013 PFF's at PFIZER's discretion. Programs will be paid by credit memo or check.

Exhibit E

Pfizer Domestic 2012 Calendar

	
Accounting Period

	
Close Date

	
AP 1

	
01/29/12

	
AP 2

	
02/26/12

	
AP 3

	
04/01/12

	  	  
	
AP 4

	
04/29/12

	
AP 5

	
05/27/12

	
AP 6

	
07/01/12

	  	  
	
AP 7

	
07/29/12

	
AP 8

	
08/26/12

	
AP 9

	
09/30/12

	  	  
	
AP 10

	
10/28/12

	
AP 11

	
11/30/12

	
AP 12

	
12/31/12SMBL3.31.2012 EX-10.1

Exhibit 10.1

Second Amendment to Amended and Restated Credit Agreement
This Second Amendment to Amended and Restated Credit Agreement (herein, the “Amendment”) is entered into as of March __, 2012 (the “First Amendment Effective Date”), among GFA Brands, Inc., a Delaware corporation (“GFA”), Glutino USA, Inc., a Delaware corporation (“Glutino,” and together with GFA, each a “Borrower” and collectively, the “Borrowers”), Smart Balance, Inc., a Delaware corporation (the “Parent”), as a Guarantor, SB Glutino, L.P., a Delaware limited partnership (“SB Glutino”), as a Guarantor, the direct and indirect Subsidiaries of the Borrower from time to time party to the Credit Agreement (hereafter defined), as Guarantors (together with the Parent and SB Glutino, the “Guarantors”), the several financial institutions from time to time party to this Agreement, as Lenders (the “Lenders”), and Bank of Montreal, a Canadian chartered bank acting through its Chicago branch, as Administrative Agent (the “Administrative Agent”).
Preliminary Statements
A.    The Borrowers, the Parent, SB Glutino, the other Guarantors, the Lenders and the Administrative Agent are currently party to that certain Amended and Restated Credit Agreement dated as of March 31, 2011 (such Amended and Restated Credit Agreement, as the same has been amended prior to the date hereof, being referred to herein as the “Credit Agreement”).  All capitalized terms used herein without definition shall have the same meanings herein as such terms have in the Credit Agreement.
B.    The Borrowers have requested that the Lenders make a certain amendment to the Credit Agreement, and the Lenders are willing to do so under the terms and conditions set forth in this Amendment.
Now, Therefore, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:
		
	Section 1.
	Amendment.

1.1.    Subject to the satisfaction (or waiver by the Administrative Agent) of the conditions precedent set forth in Section 2 below, the defined term “Excess Cash Flow” set forth in Section 5.1 of the Credit Agreement is hereby amended in its entirety and as so amended shall be restated to read as follows:
“Excess Cash Flow” means, with respect to any period (without duplication), the amount (if any) by which (a) EBITDA (but determined for such purposes without giving effect to any extraordinary gains or losses or pro forma results from Acquisitions for the period prior to the consummation thereof) during such period exceeds (b) the sum of (i) Interest Expense payable in cash during such period, plus (ii) federal, state and local income and franchise taxes payable in cash during such period, plus (iii) the aggregate amount of payments required to be made, and actually made, by the Parent, the Borrower and its Subsidiaries during such period in respect of all principal on all Indebtedness of Borrowed Money (whether at maturity, as a result of 

mandatory sinking fund redemption, mandatory prepayment, acceleration or otherwise, but excluding payments made under the Revolving Credit and excluding prepayments of the Term Loans made under Section 1.9 hereof), plus (iv) the aggregate amount of Capital Expenditures made by the Parent, the Borrower and its Subsidiaries during such period to the extent permitted by this Agreement and not financed with proceeds of Indebtedness for Borrowed Money (but excluding credit extended under the Revolving Credit), plus (v) any increases in non‐debt, non‐cash working capital of the Parent, the Borrower and its Subsidiaries for such period, plus (vi) cash expenses incurred in connection with the termination of hedging agreements of any Glutino Subsidiary, plus (vii) long-term incentive compensation for employees of any Glutino Subsidiary, plus (viii) costs and expenses incurred by any Glutino Subsidiary prior to the date of the Glutino Acquisition, which shall not be incurred after the consummation of the Glutino Acquisition (e.g., management fees) to the extent included in Net Income, plus (ix) integration expenses (including severance, relocation, plant consolidation and related items) arising from the Glutino Acquisition in an aggregate amount not to exceed $2,000,000; provided, however, such integration expenses must be incurred and paid prior to the third anniversary of the consummation of the Glutino Acquisition, plus (x) transaction expenses and charges paid by the Parent or any Subsidiary directly relating to the Glutino Acquisition in an aggregate amount not to exceed $5,000,000 minus (xi) any decreases in non‐debt, non‐cash working capital of the Parent, the Borrower and its Subsidiaries for such period.
		
	Section 2.
	Conditions Precedent.

2.1.    The effectiveness of this Amendment is subject to the satisfaction (or waiver by the Administrative Agent) of all of the following conditions precedent:
(a)    GFA, Glutino, the Guarantors, the Required Lenders, and the Administrative Agent shall have executed and delivered this Amendment; and
(b)    the Administrative Agent shall have received for the account of the Lenders copies (executed or certified, as may be appropriate) of all legal documents or proceedings taken in connection with the execution and delivery of this Amendment and such other agreements, instruments, documents, certificates, and opinions as the Administrative Agent or its counsel may reasonably request, each in form and substance reasonably satisfactory to the Administrative Agent.
		
	Section 3.
	Representations.

In order to induce the Lenders to execute and deliver this Amendment:
3.1.    Each of GFA and Glutino hereby represents to the Lenders that as of the date hereof this Amendment has been duly authorized, executed and delivered thereby.
3.2.    Each of GFA and Glutino hereby represents to the Lenders that as of the date hereof (i) no Default or Event of Default has occurred and is continuing under the Credit Agreement or shall result after giving effect to this Amendment and (b) the representations and warranties set forth in Section 6 of the Credit 

Agreement are true and correct (except that the representations contained in Section 6.5 shall be deemed to refer to the most recent financial statements delivered to the Administrative Agent pursuant thereto) in all material respects and that any other representations and warranties which relate to a specific date are true and correct as of such date.
		
	Section 4.
	Miscellaneous.

4.1.    Notwithstanding anything in the Credit Agreement (including, without limitation, Section 11.12 thereof) to the contrary, by the execution and delivery of this Amendment, the Lenders hereby authorize the Administrative Agent to take such action (and execute and deliver such documents, including amendments to the Collateral Documents) on the Lenders' behalf as the Administrative Agent determines is reasonably necessary or appropriate, in its sole discretion, to carry out its obligations under Section 2 above.
4.2.    Each of GFA and Glutino heretofore executed and delivered to the Administrative Agent the Security Agreement and certain other Collateral Documents. Each of GFA and Glutino hereby acknowledges and agrees that the Liens created and provided for by the Collateral Documents continue to secure, among other things, the Obligations arising under the Credit Agreement as amended hereby; and the Collateral Documents and the rights and remedies of the Administrative Agent thereunder, the obligations of each of GFA and Glutino thereunder, and the Liens created and provided for thereunder remain in full force and effect and shall not be affected, impaired or discharged hereby.  Nothing herein contained shall in any manner affect or impair the priority of the liens and security interests created and provided for by the Collateral Documents as to the indebtedness which would be secured thereby prior to giving effect to this Amendment.
4.3.    Except as specifically amended herein, the Credit Agreement shall continue in full force and effect in accordance with its original terms.  Reference to this specific Amendment need not be made in the Credit Agreement, the Notes, or any other instrument or document executed in connection therewith, or in any certificate, letter or communication issued or made pursuant to or with respect to the Credit Agreement, any reference in any of such items to the Credit Agreement being sufficient to refer to the Credit Agreement as amended hereby.
4.4.    Each of GFA and Glutino agrees to pay on demand all costs and expenses of or incurred by the Administrative Agent in connection with the negotiation, preparation, execution and delivery of this Amendment, including the reasonable fees and expenses of counsel for the Administrative Agent.
4.5.    This Amendment may be executed in any number of counterparts, and by the different parties on different counterpart signature pages, all of which taken together shall constitute one and the same agreement.  Any of the parties hereto may execute this Amendment by signing any such counterpart and each of such counterparts shall for all purposes be deemed to be an original.  Delivery of a counterpart hereof by facsimile transmission or by e‐mail transmission of an Adobe portable document format file (also known as a “PDF” file) shall be effective as delivery of a manually executed counterpart hereof.  This Amendment shall be governed by the internal laws of the State of Illinois.
[Signature Page to Follow.]
This Second Amendment to Amended and Restated Credit Agreement is entered into as of the date and year first above written.
“Borrowers”

GFA Brands, Inc.
		
	By
	 /s/ Christine Sacco    

Name:    Christine Sacco
Title:    Chief Financial Officer, Treasurer
Glutino USA, Inc.
By /s/ Christine Sacco    
Name:    Christine Sacco
Title:    Vice President and Assistant Secretary
“Guarantors”
Smart Balance, Inc.
		
	By
	/s/ Norman J. Matar

Name:    Norman J. Matar
Title:    EVP, General Counsel
SB Glutino, L.P.
		
	By
	/s/ Christine Sacco

Name:    Christine Sacco
Title:    Chief Financial Officer
Accepted and agreed to.
“Administrative Agent and L/C Issuer”
Bank of Montreal, as L/C Issuer and as Administrative Agent
		
	By
	/s/ Philip Langheim

Name    Philip Langheim
Title    Managing Director
“Lenders”
Bank of Montreal

		
	By
	/s/ Philip Langheim

Name  Philip Langheim    
Title    Managing Director
General Electric Capital Corporation, as a Lender
		
	By:
	/s/ Jun Young

Name:    Jun Young
Title: Duly Authorized Signatory
GE Capital Financial Inc., as a Lender
		
	By:
	/s/  (illegible)

Name:    (illegible)
Title: Duly Authorized Signatory
Union Bank, N.A.
		
	By
	/s/ Pierre Bury

Name    Pierre Bury
Title    VP
Siemens Financial Services, inc.
		
	By
	/s/ (illegible)

Name    (illegible)
Title    (illegible)
		
	By
	/s/ Paul Ramseur

Name    Paul Ramseur
Title    Vice President/Head of Risk Mgt.
Fifth Third Bank
		
	By
	/s/ Marc Crady

Name    Marc Crady
Title    Vice President
KeyBank National Association
		
	By
	/s/ Thomas A. Crandell

Name    Thomas A. Crandell

Title    Senior Vice President
ING Capital LLC
		
	By
	/s/ Daniel W. Lamprecht

Name    Daniel W. Lamprecht
Title    Managing Director

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00203-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00203-of-00352.parquet"}]]